Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Novartis Says Gilenya Showed Positive Clinical Outcomes In Phase III 2309 Study

RELATED NEWS
Trade NVS now with 

Novartis AG (NVS: Quote) announced new data from the Phase III 2309 study showing patients with relapsing-remitting multiple sclerosis, or RRMS, treated with Gilenya, or fingolimod, had a statistically significant 48% reduction in annualized relapse rates at 24 months compared to placebo.

According to the company, study 2309 is the third Phase III clinical trial to demonstrate a significant reduction of relapse rates with Gilenya treatment in patients with RRMS.

Novartis noted that a reduction of brain volume loss, a pre-defined key secondary endpoint for study 2309, also achieved statistical significance for Gilenya-treated patients compared to placebo. Brain volume loss is valued as a predictor of long-term disability.

Moreover, safety and tolerability were broadly consistent with previous clinical trials.

"Study 2309 confirms the efficacy of Gilenya across several key measures, including reductions in annualized relapse rate and reductions in brain volume loss," said David Epstein, Head of the Pharmaceuticals Division at Novartis Pharma AG. "With more than 20,000 patient years of fingolimod exposure to date, Gilenya continues to demonstrate its value to patients and the MS community. We are looking forward to presenting the full data to the clinical community at a scientific congress next year."

Register
To receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A UN report describing terrible atrocities carried out by Islamic State militants in Syria says children as young as 10 are being recruited and trained at ISIS camps as fighters. The report, based on 480 interviews and and evidence collected between 20 January and 15 July, chronicles the unimaginable brutality and human cost of the Syrian conflict. The report by the independent international com Poverty in Latin America and the Caribbean has been reduced by almost half in the last decade, and the middle class grew by 82 million people, from 21 percent of the population in 2000 to 34 percent in 2012, according to new data released by the United Nations Development Program (UNDP). UNDP's analysis, based on data from the Center for Distributive, Labor and Social Studies (CEDLAS), highlights German consumer sentiment is set to weaken in September for the first time since early 2013 as intensified geopolitical tensions are likely to shift the economy into lower gears. The forward-looking consumer confidence index fell to 8.6 from a revised score of 8.9 in August, a survey by the market research group GfK, based on responses from 2,000 households, showed Wednesday.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.